New Drug Indication Approvals

New drug indication approval - March 2024

Audiences

Healthcare professional

Industry member

Product type

Therapeutic Products

7 May 2024

This article has been migrated from an earlier version of the site and may display formatting inconsistencies.

For the most updated information related to registered therapeutic products, please refer to the Register of Therapeutic Products.

Table caption

Product Name	SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML
Active Ingredient (Strength)	Risankizumab(75mg/0.83mL), Risankizumab(150mg), Risankizumab(150mg/mL)
Product Registrant	ABBVIE PTE. LTD.
Date of Approval	26/03/2024
Indications: SKYRIZI is indicated for the treatment of moderate to severe palmoplantar pustulosis in adults who do not adequately respond or are intolerant to conventional therapy.

Table caption

Product Name	ERBITUX 5MG/ML
Active Ingredient (Strength)	Cetuximab, chimeric antibody(5mg/ml)
Product Registrant	MERCK PTE. LTD.
Date of Approval	18/03/2024
Indications: Erbitux is indicated in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.